131 related articles for article (PubMed ID: 16770642)
1. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.
Sapino A; Marchiò C; Senetta R; Castellano I; Macrì L; Cassoni P; Ghisolfi G; Cerrato M; D'Ambrosio E; Bussolati G
Virchows Arch; 2006 Sep; 449(3):288-96. PubMed ID: 16770642
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
Drev P; Grazio SF; Bracko M
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
[TBL] [Abstract][Full Text] [Related]
3. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
4. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer.
Alnajar H; Rosen L; Javidiparsijani S; Al-Ghamdi Y; Gattuso P
Acta Cytol; 2017; 61(2):140-144. PubMed ID: 28231581
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
10. Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women.
Alkushi A
Hematol Oncol Stem Cell Ther; 2009; 2(3):394-8. PubMed ID: 20139052
[TBL] [Abstract][Full Text] [Related]
11. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
12. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
14. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
15. Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients.
Stämpfli SF; Akhmedov A; Hausladen S; Varga Z; Dedes KJ; Hellermann J; Lüscher TF; Kristiansen G; Tanner FC; Breitenstein A
Anticancer Res; 2017 Jun; 37(6):3259-3264. PubMed ID: 28551673
[TBL] [Abstract][Full Text] [Related]
16. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
[No Abstract] [Full Text] [Related]
19. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
20. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
